Agrawal Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 17-07-2024
- Paid Up Capital ₹ 38.05 K
as on 17-07-2024
- Company Age 36 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 6.11 Cr
as on 17-07-2024
- Satisfied Charges ₹ 6.80 Cr
as on 17-07-2024
- Revenue -21.36%
(FY 2022)
- Profit -58.66%
(FY 2022)
- Ebitda -47.62%
(FY 2022)
- Net Worth 8.46%
(FY 2022)
- Total Assets 6.83%
(FY 2022)
About Agrawal Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 38.05 K .
The company currently has active open charges totaling ₹6.11 Cr. The company has closed loans amounting to ₹6.80 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sumeet Agrawal, Ashok Agrawal, Ranjana Goyal, and One other member serve as directors at the Company.
- CIN/LLPIN
U74899DL1988PTC031163
- Company No.
031163
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Mar 1988
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Agrawal Drugs Private Limited offer?
Agrawal Drugs Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Fertilizers and Soil Additives, Micronutrient Fertilizers, Ayurvedic,Herbal Products & Medicine, Herbal Oil, Hand Sanitizers & Personal Hygiene, Hand Wash, Essential & Aromatic Oils, Carrier Oil.
Who are the key members and board of directors at Agrawal Drugs?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumeet Agrawal  | Managing Director | 16-Feb-2001 | Current |
| Ashok Agrawal | Managing Director | 14-Jul-2005 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ranjana Goyal | Director | 22-Jun-1998 | Current |
| Nidhi Agrawal | Director | 14-Jul-2005 | Current |
Financial Performance of Agrawal Drugs.
Agrawal Drugs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 21.36% decrease. The company also saw a substantial fall in profitability, with a 58.66% decrease in profit. The company's net worth moved up by a moderate rise of 8.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agrawal Drugs?
In 2022, Agrawal Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Jan 2024 | ₹1.61 M | Open |
Sidbi Creation Date: 25 Jan 2023 | ₹4.53 M | Open |
Sidbi Creation Date: 30 Mar 2020 | ₹5.00 M | Open |
How Many Employees Work at Agrawal Drugs?
Agrawal Drugs has a workforce of 55 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agrawal Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agrawal Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
